According to the guidelines of the European Society for Medical Oncology and several clinical studies, use of bisphosphonates (e.g., zoledronic acid) or anti-receptor activator of nuclear factor κB (NF-κB) ligand (anti-RANKL) monoclonal antibody (e.g., denosumab) is recommended for the treatment of lung cancer patients with bone metastasis (5–9). This evidence concerns the gene NFKB1 and lung carcinoma.